BridgeBio Pharma stock
BBIONASDAQBridgeBio Pharma, Inc., HealthcareISIN US10806X1028
49Score 49 out of 100, Weak
Price and trend
67 / 100
Price history
+18% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 7.5% above it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 71).
The price is 13% below its 52-week high. Largest decline in 7 years: 93% (February 2021 to May 2022).
Chart figures for advanced users
- SMA 50$69.92
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$72.70
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)71
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$63.30
- The lowest closing price of the last twelve months.
- Resistance$90.17
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- BridgeBio Pharma, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $15.23B, is number 24 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $502.08M (up 126.3% year on year) and a loss of $729.31M.
- For fiscal 2026, analysts expect on average revenue of $1.09B (up 117%) and adjusted earnings per share of −$2.68.
Show more
- MEQIRI Score 49 out of 100 (Weak): rank 385 of 702 in Healthcare, median 53.
- Our model puts fair value at $199.53, with the price 61% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 127.4% a year since 2020, Biotechnology median 19.4%.Growth 70
Weaknesses
- DilutionShare count up 67% since 2020.Capital allocation 18
- Loss-makingLoss of $570.21M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$374.31M over the last 12 months.Fundamentals 17
Its standout strengths are valuation and momentum, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 50 to 49.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 23 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- weak fundamentals
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $142.52 and expensive above $332.56 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 9.9%. At 10.9% the fair value would be $167.71, at 8.9% it would be $244.20.
Possible value trap: looks cheap, but score below 50, weak balance sheet.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 126% on the prior year. Revenue turned from negative at the start of the period to positive ($502.08M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 94%, operating −113%, net −145%. Last 12 months: net −60%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 23 Feb 2027in 102 days
- Last reported
- 29 Oct 2026EPS reported −$0.42 (expected −$0.54)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 504.0% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$2.68+3.4%
- Revenue
- $1.09B+6.0%
- Earnings per share
- −$0.81−504.0%
- Revenue
- $1.66B−1.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 7 insiders sold, $37.21M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Apuli MaricelSale
30 Oct 2026, Chief Accounting Officer
- Shares
- 2,000
- Price
- $72.85
- Value
- $145,700
- Kumar NeilSale
17 Sept 2026, Chief Executive Officer
- Shares
- 10,000
- Price
- $69.08
- Value
- $690,847
- Kumar NeilSale
19 Aug 2026, Chief Executive Officer
- Shares
- 10,000
- Price
- $84.03
- Value
- $840,257
Show 14 more
- Kumar NeilSale
18 Aug 2026, Chief Executive Officer
- Shares
- 34,980
- Price
- $82.53
- Value
- $2.89M
- Apuli MaricelSale
30 Jul 2026, Chief Accounting Officer
- Shares
- 2,000
- Price
- $80.06
- Value
- $160,120
- Ellis AndreaSale
9 Jul 2026, Board
- Shares
- 17,167
- Price
- $84.00
- Value
- $1.44M
- Cook Jennifer E.Sale
9 Jul 2026, Board
- Shares
- 148,589
- Price
- $88.54
- Value
- $13.16M
- Cook Jennifer E.Sale
24 Jun 2026, Board
- Shares
- 37,167
- Price
- $70.00
- Value
- $2.6M
- Cook Jennifer E.Sale
23 Jun 2026, Board
- Shares
- 2,196
- Price
- $68.57
- Value
- $150,580
- Valantine HannahSale
23 Jun 2026, Board
- Shares
- 2,196
- Price
- $68.57
- Value
- $150,580
- Valantine HannahSale
22 Jun 2026, Board
- Shares
- 2,808
- Price
- $68.00
- Value
- $190,944
- Cook Jennifer E.Sale
15 Jun 2026, Board
- Shares
- 90,240
- Price
- $66.62
- Value
- $6.01M
- Kumar NeilSale
5 Jun 2026, Chief Executive Officer
- Shares
- 40,000
- Price
- $67.88
- Value
- $2.72M
- Kumar NeilSale
4 Jun 2026, Chief Executive Officer
- Shares
- 40,000
- Price
- $67.46
- Value
- $2.7M
- Kumar NeilSale
21 May 2026, Chief Executive Officer
- Shares
- 26,103
- Price
- $69.44
- Value
- $1.81M
- Trimarchi ThomasSale
18 May 2026, President and CFO
- Shares
- 13,651
- Price
- $65.08
- Value
- $888,419
- Scott Randal W.Sale
15 May 2026, Board
- Shares
- 10,000
- Price
- $67.15
- Value
- $671,456
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at BridgeBio Pharma
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 49
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Ascendis PharmaASND $17.57B69
- ExelixisEXEL $17.55B90
- Neurocrine BiosciencesNBIX $17.15B77
- Jazz PharmaceuticalsJAZZ $15.43B66
- Sichuan Kelun-Biotech Biopharmaceutical6990.HK $13.9B49
- Kymera TherapeuticsKYMR $12.73B45
- Madrigal PharmaceuticalsMDGL $12.44B33
- Pharmaron Beijing300759.SZ $12.15B58
ETFs that hold BridgeBio Pharma
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 2.59% | 0.49% | €26.29M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.98% | 0.35% | €1.25B |
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 0.80% | 0.25% | €45.16M |
Show 5 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.18% | 0.43% | €2.5B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.11% | 0.45% | €1.54B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.10% | 0.10% | €395.74M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.03% | 0.25% | €178.55M |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.01% | 0.24% | €1.69B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak since 13 Nov 2026, previously Neutral
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.